SNRK

Summary

SNRK (SNF related kinase, HGNC:30598) is a protein-coding gene on chromosome 3p22.1, encoding SNF-related serine/threonine-protein kinase (Q9NRH2). May play a role in hematopoietic cell proliferation or differentiation.

SNRK is a member of the sucrose nonfermenting (SNF)-related kinase family of serine/threonine kinases (Kertesz et al., 2002 [PubMed 12234663]).

Source: NCBI Gene 54861 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 94 total
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_017719

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30598
Approved symbol	SNRK
Name	SNF related kinase
Location	3p22.1
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20224, HSNFRK, KIAA0096
Ensembl gene	ENSG00000163788
Ensembl biotype	protein_coding
OMIM	612760
Entrez	54861

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 14 protein_coding, 2 protein_coding_CDS_not_defined, 2 retained_intron

ENST00000296088, ENST00000429705, ENST00000437827, ENST00000454177, ENST00000462810, ENST00000468628, ENST00000481892, ENST00000484791, ENST00000852137, ENST00000852138, ENST00000852139, ENST00000852140, ENST00000852141, ENST00000852142, ENST00000852143, ENST00000852144, ENST00000954396, ENST00000954397

RefSeq mRNA: 3 — MANE Select: NM_017719 NM_001100594, NM_001330750, NM_017719

CCDS: CCDS43075, CCDS82759

Canonical transcript exons

ENST00000296088 — 7 exons

Exon	Start	End
ENSE00001078229	43343344	43343478
ENSE00001078234	43303098	43303792
ENSE00001078235	43340287	43340499
ENSE00001536238	43299754	43299815
ENSE00001879918	43286540	43286675
ENSE00001957391	43347339	43351143
ENSE00003604915	43332169	43332310

Expression profiles

Bgee: expression breadth ubiquitous, 297 present calls, max score 98.29.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 26.2260 / max 1183.2386, expressed in 1793 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
36302	22.1090	1791
36303	4.1171	807

Top tissues by expression

297 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
pericardium	UBERON:0002407	98.29	gold quality
visceral pleura	UBERON:0002401	97.19	gold quality
skin of hip	UBERON:0001554	97.05	gold quality
lower lobe of lung	UBERON:0008949	96.92	gold quality
cerebellar vermis	UBERON:0004720	96.76	gold quality
buccal mucosa cell	CL:0002336	96.73	gold quality
pleura	UBERON:0000977	96.60	gold quality
parietal pleura	UBERON:0002400	96.36	gold quality
superficial temporal artery	UBERON:0001614	95.89	gold quality
vena cava	UBERON:0004087	95.87	gold quality
urethra	UBERON:0000057	95.75	gold quality
renal medulla	UBERON:0000362	95.68	gold quality
bone marrow	UBERON:0002371	95.54	gold quality
lateral nuclear group of thalamus	UBERON:0002736	95.54	gold quality
pons	UBERON:0000988	95.40	gold quality
endothelial cell	CL:0000115	95.19	gold quality
penis	UBERON:0000989	94.92	gold quality
bronchial epithelial cell	CL:0002328	94.77	gold quality
trabecular bone tissue	UBERON:0002483	94.69	gold quality
cervix epithelium	UBERON:0004801	94.40	gold quality
cardia of stomach	UBERON:0001162	94.35	gold quality
upper leg skin	UBERON:0004262	94.28	gold quality
synovial joint	UBERON:0002217	94.19	gold quality
middle temporal gyrus	UBERON:0002771	94.19	gold quality
adult organism	UBERON:0007023	93.99	gold quality
bone marrow cell	CL:0002092	93.93	gold quality
epithelium of bronchus	UBERON:0002031	93.84	gold quality
jejunal mucosa	UBERON:0000399	93.81	gold quality
mucosa of paranasal sinus	UBERON:0005030	93.80	gold quality
bronchus	UBERON:0002185	93.78	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	7.05

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

132 targeting SNRK, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-513A-5P	100.00	69.77	2465
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-10401-5P	99.99	65.79	948
HSA-MIR-103A-3P	99.98	69.14	1595
HSA-MIR-107	99.98	69.14	1595
HSA-MIR-3692-3P	99.98	70.27	2139
HSA-MIR-499A-5P	99.98	70.79	1323
HSA-MIR-4789-5P	99.98	70.76	2721
HSA-MIR-3065-5P	99.97	71.56	3281
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-548AA	99.96	70.64	3753
HSA-MIR-548AP-3P	99.96	70.64	3753
HSA-MIR-548T-3P	99.96	70.64	3753
HSA-MIR-302E	99.96	70.74	2669
HSA-MIR-23A-3P	99.95	74.24	3163
HSA-MIR-23B-3P	99.95	74.24	3163
HSA-MIR-23C	99.95	73.92	3192
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-219A-5P	99.91	73.36	735
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798

Literature-anchored findings (GeneRIF, showing 8)

• SNRK could mediate some of the physiological effects of LKB1 (PMID:15733851)
• SNRK inhibits colon cancer cell proliferation through calcyclin-binding protein up-regulation and beta-catenin degradation, which results in reduced proliferation signaling. (PMID:22874833)
• These findings reveal a novel function for SNRK in the regulation of colon cancer cell proliferation and beta-catenin signaling. (PMID:22874833)
• SNRK in cardiomyocytes is responsible for maintaining cardiac metabolic homeostasis, which is mediated in part by ROCK, and alteration of this homeostasis influences cardiac function in the adult heart. (PMID:27780848)
• Study shows that TRIB3 binds to SNRK, and downregulates UCP3 through PPARalpha. SNRK is increased in cardiomyopathy patients, and SNRK reduces infarct size after ischaemia/reperfusion. SNRK also decreases cardiac cell death in a UCP3-dependent manner. (PMID:28117339)
• Differential expression of SNRK in early versus late stage disease suggests specific roles for SNRK in ovarian cancer metastasis. (PMID:28722495)
• Report the crystal structure of an N-terminal SNRK fragment containing kinase and adjacent ubiquitin-associated (UBA) domains. This structure shows that the UBA domain binds between the N- and C-lobes of the kinase domain. The mode of UBA binding in SNRK largely resembles that in AMPK and brain specific kinase (BRSK), however, unique interactions play vital roles in stabilizing the KD-UBA interface of SNRK. (PMID:29061304)
• Human bone marrow mesenchymal stem cell-derived extracellular vesicles reduce inflammation and pyroptosis in acute kidney injury via miR-223-3p/HDAC2/SNRK. (PMID:36640195)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	snrka	ENSDARG00000070832
mus_musculus	Snrk	ENSMUSG00000038145
rattus_norvegicus	Snrk	ENSRNOG00000004050
drosophila_melanogaster	Snrk	FBGN0033915
caenorhabditis_elegans		WBGENE00012638
caenorhabditis_elegans	ZK524.4	WBGENE00013994
caenorhabditis_elegans	tag-344	WBGENE00015230
caenorhabditis_elegans		WBGENE00044388

Paralogs (17): NUAK1 (ENSG00000074590), PRKAA1 (ENSG00000132356), TSSK4 (ENSG00000139908), HUNK (ENSG00000142149), SIK1 (ENSG00000142178), BRSK1 (ENSG00000160469), SIK3 (ENSG00000160584), PRKAA2 (ENSG00000162409), TSSK3 (ENSG00000162526), NUAK2 (ENSG00000163545), MELK (ENSG00000165304), SIK2 (ENSG00000170145), BRSK2 (ENSG00000174672), NIM1K (ENSG00000177453), TSSK6 (ENSG00000178093), TSSK2 (ENSG00000206203), TSSK1B (ENSG00000212122)

Protein

Protein identifiers

SNF-related serine/threonine-protein kinase — Q9NRH2 (reviewed: Q9NRH2)

Alternative names: SNF1-related kinase

All UniProt accessions (2): Q9NRH2, E7EUC4

UniProt curated annotations — full annotation on UniProt →

Function. May play a role in hematopoietic cell proliferation or differentiation. Potential mediator of neuronal apoptosis.

Subcellular location. Nucleus.

Tissue specificity. Expressed in hematopoietic progenitor cells and leukemic cell lines. Weakly expressed in the testis.

Post-translational modifications. Autophosphorylated. Phosphorylation on Thr-173 by STK11/LKB1 in complex with STE20-related adapter-alpha (STRADA) pseudo kinase and CAB39.

Activity regulation. Activated by phosphorylation on Thr-173.

Similarity. Belongs to the protein kinase superfamily. CAMK Ser/Thr protein kinase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NRH2-1	1	yes
Q9NRH2-2	2

RefSeq proteins (3): NP_001094064, NP_001317679, NP_060189* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR015940	UBA	Domain
IPR017441	Protein_kinase_ATP_BS	Binding_site

Pfam: PF00069

Catalyzed reactions (Rhea), 2 shown:

• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (64 total): helix 14, sequence conflict 13, modified residue 9, strand 6, sequence variant 5, compositionally biased region 4, turn 3, domain 2, binding site 2, splice variant 2, chain 1, mutagenesis site 1, region of interest 1, active site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
5YKS	X-RAY DIFFRACTION	2.9

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NRH2-F1	57.94	0.22

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 139 (proton acceptor)

Ligand- & substrate-binding residues (2): 45; 22–30

Post-translational modifications (9): 162, 173, 362, 390, 482, 495, 518, 534, 607

Mutagenesis-validated functional residues (1):

Position	Phenotype
173	prevents phosphorylation and activation by stk11/lkb1 complex.

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 272 (showing top): GOBP_MYELOID_CELL_DIFFERENTIATION, AAGCAAT_MIR137, GNF2_CASP8, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, TGCACTT_MIR519C_MIR519B_MIR519A, MODULE_45, AAGCCAT_MIR135A_MIR135B, BROWNE_HCMV_INFECTION_16HR_UP, BROWNE_HCMV_INFECTION_12HR_UP, AATGGAG_MIR136, MODULE_66, CAIRO_HEPATOBLASTOMA_CLASSES_DN, GGGCATT_MIR365, RICKMAN_TUMOR_DIFFERENTIATED_WELL_VS_POORLY_DN, DEURIG_T_CELL_PROLYMPHOCYTIC_LEUKEMIA_DN

GO Biological Process (3): protein phosphorylation (GO:0006468), myeloid cell differentiation (GO:0030099), cell division (GO:0051301)

GO Molecular Function (9): magnesium ion binding (GO:0000287), protein serine/threonine kinase activity (GO:0004674), ATP binding (GO:0005524), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein kinase activity (GO:0004672), kinase activity (GO:0016301), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), spindle (GO:0005819)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein kinase activity	2
phosphorylation	1
protein modification process	1
hemopoiesis	1
cell differentiation	1
cellular process	1
metal ion binding	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
kinase activity	1
phosphotransferase activity, alcohol group as acceptor	1
catalytic activity, acting on a protein	1
transferase activity, transferring phosphorus-containing groups	1
catalytic activity	1
cation binding	1
intracellular membrane-bounded organelle	1
microtubule cytoskeleton	1
intracellular membraneless organelle	1

Protein interactions and networks

STRING

752 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SNRK	DUSP5	Q16690	837
SNRK	CAB39	Q9Y376	811
SNRK	DUSP2	Q05923	762
SNRK	SFRP4	Q6FHJ7	720
SNRK	HEY2	Q9UBP5	667
SNRK	DUSP1	P28562	636
SNRK	PIK3C2A	O00443	574
SNRK	STK11	Q15831	499
SNRK	CD38	P28907	494
SNRK	PPP3R2	Q96LZ3	479
SNRK	HSP90AA1	P07900	460
SNRK	PIK3AP1	Q6ZUJ8	455
SNRK	ZNF346	Q9UL40	447
SNRK	CHP1	Q99653	446
SNRK	PTEN	P60484	437

IntAct

20 interactions, top by confidence:

A	B	Type	Score
GDF5	SERPINB7	psi-mi:“MI:0914”(association)	0.530
SLC31A1	C2orf72	psi-mi:“MI:0914”(association)	0.530
SNRK	ABHD5	psi-mi:“MI:0915”(physical association)	0.400
SNRK	YWHAE	psi-mi:“MI:0915”(physical association)	0.400
SFN	SNRK	psi-mi:“MI:0915”(physical association)	0.400
SNRK	MME	psi-mi:“MI:0915”(physical association)	0.400
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
ADAMTS12	FKBP9	psi-mi:“MI:0914”(association)	0.350
SNRK	PRPF6	psi-mi:“MI:0914”(association)	0.350
CAMK2A	OGT	psi-mi:“MI:0914”(association)	0.350
KCNE3	PIK3R2	psi-mi:“MI:0914”(association)	0.350
CAMK2A	SMCHD1	psi-mi:“MI:0914”(association)	0.350
CAMK2A	ARHGAP32	psi-mi:“MI:0914”(association)	0.350
CAMK2A	MAP3K7	psi-mi:“MI:0914”(association)	0.350
SNRK	STK11	psi-mi:“MI:0217”(phosphorylation reaction)	0.310
STK16	SNRK	psi-mi:“MI:0915”(physical association)	0.000
SNRK	glyQS	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (38): SNRK (Affinity Capture-MS), SNRK (Affinity Capture-MS), SNRK (Affinity Capture-MS), SNRK (Affinity Capture-MS), ABHD5 (Affinity Capture-MS), STK16 (Affinity Capture-MS), SNRK (Affinity Capture-RNA), TRIB3 (Affinity Capture-Western), SNRK (Affinity Capture-MS), SNRK (Affinity Capture-MS), SNRK (Affinity Capture-MS), SNRK (Affinity Capture-MS), SNRK (Affinity Capture-MS), MME (Affinity Capture-MS), SNRK (Affinity Capture-MS)

ESM2 similar proteins: A0A078CGE6, A2QHV0, A7KAX9, A7SNN5, A9RVK2, B0XPE7, B5X564, D0Z5N4, F4HYG2, F4I114, F4IRW0, F4J394, F4J6F6, F4JY37, O00444, O13839, O24527, O43065, P0CP71, P13185, P38623, P42858, P50526, Q03407, Q0CL79, Q0WPH8, Q14693, Q19192, Q2KHT3, Q2QAV0, Q4WJI7, Q5B4Z3, Q5R9Z7, Q60DG4, Q6GPD0, Q6H647, Q756Z0, Q75CH3, Q75DK7, Q75QN6

Diamond homologs: A0AUV4, A1A5Q6, A2KF29, A2XFF4, A8WYE4, B2DD29, B7XHR6, B8BBT7, C0HKC8, C0HKC9, F1QGZ6, O08678, O08679, O22932, O22971, O65554, O74536, O94168, P27448, P52497, P54645, P54646, P57059, P92958, Q00372, Q02723, Q03141, Q05512, Q09137, Q0D4B2, Q0JI49, Q13131, Q19469, Q28948, Q2QY53, Q2RAX3, Q2V452, Q38997, Q54DF2, Q54TA3

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
STK11	“up-regulates activity”	SNRK	phosphorylation

Disease & clinical

Clinical variants and AI predictions

ClinVar

94 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	72
Likely benign	5
Benign	6

Top pathogenic / likely-pathogenic (0)

SpliceAI

2494 predictions. Top by Δscore:

Variant	Effect	Δscore
3:43332167:A:AG	acceptor_gain	1.0000
3:43332168:G:GG	acceptor_gain	1.0000
3:43332309:GA:G	donor_gain	1.0000
3:43332311:G:GG	donor_gain	1.0000
3:43340495:GTAGA:G	donor_gain	1.0000
3:43340498:GA:G	donor_gain	1.0000
3:43340500:G:GG	donor_gain	1.0000
3:43343339:CTCA:C	acceptor_loss	1.0000
3:43343342:A:AG	acceptor_gain	1.0000
3:43343342:A:G	acceptor_loss	1.0000
3:43343343:G:GA	acceptor_gain	1.0000
3:43343343:GA:G	acceptor_gain	1.0000
3:43343343:GAGC:G	acceptor_gain	1.0000
3:43343343:GAGCC:G	acceptor_gain	1.0000
3:43343478:GGTG:G	donor_loss	1.0000
3:43343479:G:T	donor_loss	1.0000
3:43343480:T:G	donor_loss	1.0000
3:43299814:GG:G	donor_gain	0.9900
3:43299815:GG:G	donor_gain	0.9900
3:43303789:GTAG:G	donor_gain	0.9900
3:43303791:AGGTA:A	donor_loss	0.9900
3:43303793:G:GC	donor_loss	0.9900
3:43303794:T:A	donor_loss	0.9900
3:43332163:TTATA:T	acceptor_loss	0.9900
3:43332164:TATAG:T	acceptor_loss	0.9900
3:43332165:ATAGA:A	acceptor_loss	0.9900
3:43332166:TAG:T	acceptor_loss	0.9900
3:43332167:AGA:A	acceptor_loss	0.9900
3:43332168:GAT:G	acceptor_gain	0.9900
3:43332308:AGAGT:A	donor_loss	0.9900

AlphaMissense

5078 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:43303241:C:A	A13D	1.000
3:43303243:G:A	G14R	1.000
3:43303243:G:C	G14R	1.000
3:43303244:G:A	G14E	1.000
3:43303249:T:A	Y16N	1.000
3:43303249:T:C	Y16H	1.000
3:43303249:T:G	Y16D	1.000
3:43303250:A:G	Y16C	1.000
3:43303256:T:A	L18Q	1.000
3:43303256:T:C	L18P	1.000
3:43303268:T:C	L22S	1.000
3:43303268:T:G	L22W	1.000
3:43303270:G:A	G23S	1.000
3:43303270:G:C	G23R	1.000
3:43303270:G:T	G23C	1.000
3:43303271:G:A	G23D	1.000
3:43303271:G:T	G23V	1.000
3:43303276:G:A	G25S	1.000
3:43303276:G:C	G25R	1.000
3:43303276:G:T	G25C	1.000
3:43303277:G:A	G25D	1.000
3:43303277:G:C	G25A	1.000
3:43303277:G:T	G25V	1.000
3:43303282:T:A	F27I	1.000
3:43303282:T:C	F27L	1.000
3:43303282:T:G	F27V	1.000
3:43303283:T:C	F27S	1.000
3:43303283:T:G	F27C	1.000
3:43303284:T:A	F27L	1.000
3:43303284:T:G	F27L	1.000

dbSNP variants (sampled 300 via entrez): RS1000008736 (3:43288983 A>G), RS1000024042 (3:43294764 A>G), RS1000053714 (3:43304491 T>G), RS1000077760 (3:43294493 G>T), RS1000095619 (3:43326987 A>G), RS1000182693 (3:43301120 CTATT>C), RS1000295670 (3:43325346 T>A), RS1000301110 (3:43351578 T>C), RS1000370302 (3:43302011 A>G), RS1000388663 (3:43350882 G>A,C,T), RS1000444970 (3:43308122 AAG>A), RS1000546727 (3:43314938 A>G,T), RS1000596240 (3:43321254 CAGG>C), RS1000635277 (3:43349855 T>C), RS1000669751 (3:43300813 A>C,G,T)

Disease associations

OMIM: gene MIM:612760 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST001762_531	Obesity-related traits	9.000000e-06
GCST001762_789	Obesity-related traits	2.000000e-07
GCST008832_1	Gastroesophageal reflux disease	3.000000e-08

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0005188	CCL11 measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1908384 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 82,937 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1287853	FEDRATINIB	4	3,554
CHEMBL535	SUNITINIB	4	79,020
CHEMBL1721885	SU-014813	2	363

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — SNRK subfamily

ChEMBL bioactivities

9 potent at pChembl≥5 of 9 total, top 9 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.42	IC50	3.79	nM	STAUROSPORINE
8.10	IC50	8.01	nM	STAUROSPORINE
8.01	IC50	9.78	nM	STAUROSPORINE
7.05	Kd	90	nM	STAUROSPORINE
6.64	Kd	230	nM	FEDRATINIB
6.52	Kd	300	nM	TAE-684
6.19	Kd	640	nM	SUNITINIB
6.05	Kd	890	nM	CHEMBL4781866
5.82	Kd	1500	nM	SU-014813

PubChem BioAssay actives

9 with measured affinity, of 158 total; 6 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1715166: Inhibition of human SNRK using MBP as substrate by [gamma-33P]-ATP assay	ic50	0.0038	uM
Fedratinib	624752: Binding constant for SNRK kinase domain	kd	0.2300	uM
5-chloro-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrimidine-2,4-diamine	624752: Binding constant for SNRK kinase domain	kd	0.3000	uM
Sunitinib	624752: Binding constant for SNRK kinase domain	kd	0.6400	uM
N-(4-methyl-2-pyridinyl)-2-naphthalen-2-ylacetamide	1685597: Binding affinity to recombinant human SNRK E97G/P116A mutant (1 to 505 residues) using KKLRRTLSFAEPG peptide as substrate incubated for 40 mins in presence of [gamma33P]ATP by radiometric scintillation analysis	kd	0.8900	uM
5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-N-[(2S)-2-hydroxy-3-morpholin-4-ylpropyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide	624752: Binding constant for SNRK kinase domain	kd	1.5000	uM

CTD chemical–gene interactions

35 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
Valproic Acid	affects expression, increases expression	2
3-((6-(2-methoxyphenyl)pyrimidin-4-yl)amino)phenyl)methane sulfonamide	decreases expression	1
FR900359	decreases phosphorylation	1
triphenyl phosphate	affects expression	1
arsenite	affects binding, decreases reaction	1
ciglitazone	affects binding, increases expression	1
di-n-butylphosphoric acid	affects expression	1
seocalcitol	increases expression	1
CGP 52608	increases reaction, affects binding	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
PCI 5002	affects cotreatment, increases expression	1
Panobinostat	affects cotreatment, affects expression	1
Caffeine	affects phosphorylation	1
Calcitriol	increases expression	1
Cisplatin	affects cotreatment, affects expression	1
Dimethyl Sulfoxide	increases expression	1
Endosulfan	increases expression	1
Ethyl Methanesulfonate	increases expression	1
Formaldehyde	decreases expression	1
Lead	affects expression	1
Methyl Methanesulfonate	increases expression	1
Progesterone	decreases expression	1
Tetrachlorodibenzodioxin	affects expression	1
Tobacco Smoke Pollution	increases expression	1
Tretinoin	increases expression	1
Urethane	increases expression	1
Zinc	increases expression, affects cotreatment	1

ChEMBL screening assays

111 unique, capped per target: 111 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1175341	Binding	Inhibition of SNRK at 10 uM	Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. — Bioorg Med Chem Lett

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2GV	Abcam HeLa SNRK KO	Cancer cell line	Female
CVCL_TP84	HAP1 SNRK (-)	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.